Hemostemix Inc. (HEM.V)
- Newsfile
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it and CytoImmune Therapuetics ("CytoImmune") today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico. CytoImmune Therapeutics, Toa Baja, Puerto RicoTo view an enhanced version of this graphic, pleas
- Newsfile
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four heart and three chronic limb threatening ischemia (CLTI) trials, including one retrospective study of 54 patients, ACP-01 is demonstrated to be safe and statistically efficacious ...
- Newsfile
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility. The Company is also pleased to announce that it has received commitments for $1,800,000 of Units in a non-brokered private placement as more fully described below.Cyt
